A detailed history of Jefferies Group LLC transactions in Iveric Bio, Inc. stock. As of the latest transaction made, Jefferies Group LLC holds 19,510 shares of ISEE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,510
Previous 659 2860.55%
Holding current value
$0
Previous $6,000 5733.33%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Sep 21, 2023

BUY
$9.4 - $18.59 $177,199 - $350,440
18,851 Added 2860.55%
19,510 $350,000
Q3 2022

Nov 14, 2022

BUY
$9.4 - $18.59 $177,199 - $350,440
18,851 Added 2860.55%
19,510 $350,000
Q2 2022

Sep 21, 2023

SELL
$9.12 - $18.9 $18,349 - $38,026
-2,012 Reduced 75.33%
659 $6,000
Q2 2022

Aug 15, 2022

SELL
$9.12 - $18.9 $18,349 - $38,026
-2,012 Reduced 75.33%
659 $6,000
Q1 2022

Sep 21, 2023

SELL
$12.15 - $16.83 $673,644 - $933,122
-55,444 Reduced 95.4%
2,671 $44,000
Q1 2022

May 16, 2022

BUY
$12.15 - $16.83 $32,452 - $44,952
2,671 New
2,671 $45,000
Q4 2021

Feb 14, 2022

SELL
$13.83 - $18.78 $803,730 - $1.09 Million
-58,115 Closed
0 $0
Q3 2021

Sep 21, 2023

SELL
$7.07 - $17.5 $1.36 Million - $3.36 Million
-191,885 Reduced 76.75%
58,115 $943,000
Q3 2021

Nov 15, 2021

SELL
$7.07 - $17.5 $1.36 Million - $3.36 Million
-191,885 Reduced 76.75%
58,115 $944,000
Q2 2021

Sep 21, 2023

BUY
$5.69 - $7.17 $1.31 Million - $1.65 Million
230,490 Added 1181.39%
250,000 $1.58 Million
Q2 2021

Aug 16, 2021

BUY
$5.69 - $7.17 $1.42 Million - $1.79 Million
250,000 New
250,000 $1.58 Million

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.